Andra Balanescu

Publications

• Research   
  Long-term Efficacy snd Safety of Bosentan in Patients with Digit al Ulcers Related to Systemic Sclerosis
  Author(s): Laura Groseanu, Cristina Nita, Oana Naiman, Violeta Bojinca*, Andra Balanescu, Daniela Opris-Belinski, Denisa Predeteanu, Florian Berghea, Ioana Saulescu, Sanziana Daia-Iliescu, Diana Mazilu, Andreea Borangiu, Cosmin Constantinescu, Mihai Abobului and Ruxandra Ionescu
  
  Objective: Two pivotal studies, RAPIDS-1 and RAPIDS-2 (RAndomized, double-blind, Placebo-controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis) revealed that Bosentan reduces the development of new Digital Ulcers (DUs) in patients with Systemic Sclerosis (SSc). However, data regarding the long-term use of this dual endothelin antagonist receptor in the treatment of DUs is scarce. Methods: We conducted a prospective observational case-control study, between 2014 and 2020 that enrolled 80 SSc patients with at least one active DU at baseline compatible with a vascular etiology or recurrent DUs within the previous 3 months. DUs number, patients’ subjective perception of DUs’ pain and/or Raynaud’s phenomenon, nail fold video-capillaroscopy, and Health Assessment Questionnaire (HAQ) were reassessed every 6 m.. Read More»
  

  Abstract HTML PDF